文献速递免疫规划传染病防控与疫情报告

以色列和秘鲁医护人员流感疫苗效果的前瞻性队列研究(2016-2019)

Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
PubMed 文献 · Vaccine · 2021-09-09

在以色列和秘鲁的医院全职医护人员中开展三个流感季的前瞻性队列研究,共5,489人贡献10,041人季。接种率以色列47%、秘鲁32%,实验室确诊流感感染率分别为7%和2.5%。调整后疫苗效果对全部病毒以色列1%(95%CI -30%至25%),秘鲁12%(95%CI -61%至52%),均无统计学显著性。

要点

  • 医护人员流感疫苗接种率以色列47%、秘鲁32%,总体偏低。
  • 两队列疫苗效果点估计均接近零且置信区间宽,未显示保护作用。
  • 需进一步研究提高医护人员疫苗效果评估的精确性和真实世界保护力。

核心结论

  • 在以色列和秘鲁六个研究季中,使用人时模型估计的流感疫苗效果均为无效(点估计接近0且无统计学显著性)。

研究设计与样本

  • 前瞻性队列研究,纳入以色列(2016-2017至2018-2019)和秘鲁(2016至2018)全职直接接触患者的医院医护人员,共5,489人贡献10,041人季,每周两次主动监测急性呼吸道症状或发热性疾病,自采呼吸道标本行实时逆转录PCR检测。

主要发现

  • 流感疫苗接种率以色列47%、秘鲁32%;急性呼吸道症状或发热性疾病以色列3,056例、秘鲁3,538例;A或B型流感病毒感染以色列205例(7%)、秘鲁87例(2.5%)。
  • 针对所有病毒的疫苗效果:以色列1%(95%CI -30%至25%),秘鲁12%(95%CI -61%至52%)。

关键数值与推荐

  • 疫苗效果计算公式:IVE = 100 × (1 - 风险比),风险比调整了性别、年龄、职业和医院。

临床怎么用

  • 当前数据不支持医护人员流感疫苗具有显著保护效果的结论,但点估计接近零且置信区间宽,应谨慎解读并继续监测。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory-confirmed influenza illness among healthcare personnel (HCP). METHODS: HCP with direct patient contact working full-time in hospitals were followed during three influenza seasons in Israel (2016-2017 to 2018-2019) and Peru (2016 to 2018). Trivalent influenza vaccines were available at all sites, except during 2018-2019 when Israel used quadrivalent vaccines; vaccination was documented by electronic medical records, vaccine registries, and/or self-report (for vaccinations outside the hospital). Twice-weekly active surveillance identified acute respiratory symptoms or febrile illness (ARFI); self-collected respiratory specimens were tested by real-time reverse transcription polymerase chain reaction (PCR) assay. IVE was 100 × 1-hazard ratio (adjusted for sex, age, occupation, and hospital). RESULTS: Among 5,489 HCP who contributed 10,041 person-seasons, influenza vaccination coverage was 47% in Israel and 32% in Peru. Of 3,056 ARFIs in Israel and 3,538 in Peru, A or B influenza virus infections were identified in 205 (7%) in Israel and 87 (2.5%) in Peru. IVE against all viruses across seasons was 1% (95% confidence interval [CI] = -30%, 25%) in Israel and 12% (95% CI = -61%, 52%) in Peru. CONCLUSION: Estimates of IVE were null using person-time models during six study seasons in Israel and Peru.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thompson MG, Soto G, Peretz A, et al. Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019. Vaccine. 2021. PMID: 34509322. doi:10.1016/j.vaccine.2021.07.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。